Patents by Inventor Andre Lescarbeau

Andre Lescarbeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20240122925
    Abstract: The disclosure is in part directed to crystalline forms of (R)-1?-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4?-piperidin]-3-amine, its salt, and variants thereof.
    Type: Application
    Filed: December 19, 2023
    Publication date: April 18, 2024
    Inventors: Alexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
  • Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
    Patent number: 11939333
    Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: March 26, 2024
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Louis Grenier, Andre Lescarbeau, Praveen Sharma, Daniel G. Genov
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240050437
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: November 30, 2022
    Publication date: February 15, 2024
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • SHP2 phosphatase inhibitors and methods of making and using the same
    Patent number: 11890281
    Abstract: The disclosure is in part directed to crystalline forms of (R)-1?-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4?-piperidin]-3-amine, its salt, and variants thereof.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 6, 2024
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
  • SHP2 phosphatase inhibitors and methods of use thereof
    Patent number: 11629145
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 18, 2023
    Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
    Patent number: 11591336
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: February 28, 2023
    Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • Heterocyclic compounds and uses thereof
    Patent number: 11541059
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 3, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220372038
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 15, 2021
    Publication date: November 24, 2022
    Inventors: Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220340576
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: November 17, 2020
    Publication date: October 27, 2022
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220315586
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: March 21, 2019
    Publication date: October 6, 2022
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • FGFR INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20220194946
    Abstract: The disclosure is in part directed to crystalline forms of N-(4-(4-amino-5-(3-fluoro-4-(4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide, its salts, its cocrystals, and variants thereof.
    Type: Application
    Filed: November 18, 2021
    Publication date: June 23, 2022
    Inventors: André LESCARBEAU, Jethro BEAMISH-COOK, Zoe PRENTICE, Thomas KENDALL, Aaron DUMAS, Elisabeth ISAAK, Piera TRINCHERA, Oleksandr ZHURAKOVSKYI, Osama SULEIMAN
  • SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME
    Publication number: 20220135576
    Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Louis Grenier, Andre Lescarbeau, Praveen Sharma, Daniel G. Genov
  • Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
    Patent number: 11247995
    Abstract: Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: February 15, 2022
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Louis Grenier, Andre Lescarbeau, Praveen Sharma, Daniel G. Genov
  • Cyclopamine analogs
    Patent number: 11007181
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 18, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210085677
    Abstract: The disclosure is in part directed to crystalline forms of (R)-1?-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4?-piperidin]-3-amine, its salt, and variants thereof.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Inventors: Alexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
  • SHP2 phosphatase inhibitors and methods of use thereof
    Patent number: 10934302
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 2, 2021
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20210000837
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 11, 2020
    Publication date: January 7, 2021
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200392161
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: February 21, 2019
    Publication date: December 17, 2020
    Inventors: W. Patrick Walters, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Alexander M. Taylor, Levi Charles Thomas Pierce, Mark Andrew Murcko, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Kyle Konze, Markus Kristofer Dahlgren, Eric Therrien
  • PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS
    Publication number: 20200172546
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 4, 2020
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • CYCLOPAMINE ANALOGS
    Publication number: 20200121658
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Application
    Filed: July 24, 2019
    Publication date: April 23, 2020
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay